U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19NO4.ClH
Molecular Weight 337.7986
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYMORPHONE HYDROCHLORIDE

SMILES

CN1CC[C@@]23c4c5ccc(c4O[C@@]3([H])C(=O)CC[C@]2([C@@]1([H])C5)O)O.Cl

InChI

InChIKey=BCGJBQBWUGVESK-KCTCKCTRSA-N
InChI=1S/C17H19NO4.ClH/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9;/h2-3,12,15,19,21H,4-8H2,1H3;1H/t12-,15+,16+,17-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H19NO4
Molecular Weight 301.3377
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf | https://www.drugs.com/pro/oxymorphone.html

Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.

Originator

Sources: DOI:10.1021/ja01627a033

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

-339292800000
Palliative
OPANA

Approved Use

Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines).

Launch Date

-339292800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.21 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.54 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.47 ng/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.59 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.27 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.7 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17.81 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
19.28 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
36.98 ng × h/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
37.9 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.54 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.6 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.89 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
9.35 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
11.3 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYMORPHONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (mild, 4.3%)
Nausea (4.3%)
Dizziness (4.3%)
Sources:
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Disc. AE: Abdominal pain, Chest pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.4%)
Chest pain (1.4%)
Serum creatine phosphokinase increased (1.4%)
Serum creatine phosphokinase MB increased (1.4%)
Back pain (1.4%)
Sources:
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
unhealthy
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources:
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
unhealthy
Disc. AE: Opioid abuse, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Respiratory depression
Addiction
Hypotension (severe)
Sources:
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Disc. AE: Opioid abuse, Addiction...
AEs leading to
discontinuation/dose reduction:
Opioid abuse
Addiction
Respiratory depression (grade 3-5)
Withdrawal syndrome neonatal
Anaphylaxis
Hypotension (severe)
Angioedema
Hypersensitivity reaction
Adrenal insufficiency
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
Nausea 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
Vomiting mild, 4.3%
Disc. AE
20 mg 4 times / day multiple, oral
Recommended
Dose: 20 mg, 4 times / day
Route: oral
Route: multiple
Dose: 20 mg, 4 times / day
Sources:
healthy, 27–44
Health Status: healthy
Age Group: 27–44
Sex: M+F
Sources:
Abdominal pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Back pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Chest pain 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Serum creatine phosphokinase MB increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Serum creatine phosphokinase increased 1.4%
Disc. AE
79.4 mg 1 times / day multiple, oral
Highest studied dose
Dose: 79.4 mg, 1 times / day
Route: oral
Route: multiple
Dose: 79.4 mg, 1 times / day
Sources:
unhealthy, 45.5-47.5
Health Status: unhealthy
Age Group: 45.5-47.5
Sex: M+F
Sources:
Addiction Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
unhealthy
Opioid abuse Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
unhealthy
Respiratory depression Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
unhealthy
Hypotension severe
Disc. AE
0.5 mg 5 times / day multiple, intravenous
Recommended
Dose: 0.5 mg, 5 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg, 5 times / day
Sources:
unhealthy
Addiction Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
unhealthy
Opioid abuse Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
unhealthy
Respiratory depression Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
unhealthy
Hypotension severe
Disc. AE
1.5 mg 5 times / day multiple, intramuscular|subcutaneous
Recommended
Dose: 1.5 mg, 5 times / day
Route: intramuscular|subcutaneous
Route: multiple
Dose: 1.5 mg, 5 times / day
Sources:
unhealthy
Addiction Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Adrenal insufficiency Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Anaphylaxis Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Angioedema Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Hypersensitivity reaction Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Opioid abuse Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Withdrawal syndrome neonatal Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Respiratory depression grade 3-5
Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Hypotension severe
Disc. AE
20 mg 5 times / day multiple, oral
Recommended
Dose: 20 mg, 5 times / day
Route: oral
Route: multiple
Dose: 20 mg, 5 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis.
2005 Apr
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial.
2005 Dec
Evaluation of induction by use of a combination of oxymorphone and diazepam or hydromorphone and diazepam and maintenance of anesthesia by use of isoflurane in dogs with experimentally induced hypovolemia.
2005 Jul
GC-MS quantitation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in blood.
2005 Jul-Aug
Direct analysis of opiates in urine by liquid chromatography-tandem mass spectrometry.
2005 Oct
Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine.
2005 Oct
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
2005 Sep-Oct
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
2006
Dissociative anaesthesia during field and hospital conditions for castration of colts.
2006
Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.
2006 Apr 4
Oxymorphone: a review.
2006 Feb
Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
2006 Feb 16
Effects of oxymorphone and hydromorphone on the minimum alveolar concentration of isoflurane in dogs.
2006 Jan
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization.
2006 Jul
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.
2006 Jun 5
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
2006 Mar
Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory.
2006 Mar
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
2006 Mar
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery.
2006 Mar 20
Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain.
2006 Mar-Apr
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
2006 May
An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites.
2006 May
Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites.
2006 Oct
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
2006 Oct
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
2007 Apr 1
GC-MS analysis of multiply derivatized opioids in urine.
2007 Aug
Comment: Oral oxymorphone for pain management.
2007 Dec
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.
2007 Feb
Extended-duration agents for perioperative pain management.
2007 Feb
Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.
2007 Feb
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
2007 Feb
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia.
2007 Feb
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
2007 Jan
New pain management options: drugs.
2007 Jan
Oral oxymorphone (Opana).
2007 Jan 1
The effect of opiates on the activity of human placental aromatase/CYP19.
2007 Jan 15
Oral extended-release oxymorphone: a new choice for chronic pain relief.
2007 Jul
Oral oxymorphone for pain management.
2007 Jul
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
2007 Jul 2
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
2007 Jun
Nociception increases during opioid infusion in opioid receptor triple knock-out mice.
2007 Jun 29
Oxymorphone hydrochloride, a potent opioid analgesic, is not carcinogenic in rats or mice.
2007 Mar
Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis.
2007 Mar 23
Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
2007 Mar 8
Use of oral oxymorphone in the elderly.
2007 May
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base.
2007 May 30
Determination of opioid analgesics in hair samples using liquid chromatography/tandem mass spectrometry and application to patients under palliative care.
2007 Oct
Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry.
2007 Sep
Rapid analysis of metabolites and drugs of abuse from urine samples by desorption electrospray ionization-mass spectrometry.
2007 Sep
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
2008 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf
Subcutaneous or Intramuscular administration: Initiate treatment with 1mg to 1.5 mg, every 4 to 6 hours.
Route of Administration: Other
In Vitro Use Guide
Oxymorphone hydrochloride was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test) at concentrations of ≤5270 ug/plate, or in an in vitro mammalian cell chromosome aberration assay performed with human peripheral blood lymphocytes at concentrations ≤5000 ug/mL with or without metabolic activation.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:53:20 UTC 2021
Edited
by admin
on Sat Jun 26 15:53:20 UTC 2021
Record UNII
5Y2EI94NBC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYMORPHONE HYDROCHLORIDE
GREEN BOOK   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
OXYMORPHONE HYDROCHLORIDE [VANDF]
Common Name English
OXYMORPHONE HYDROCHLORIDE [MART.]
Common Name English
OPANA
Brand Name English
OXYMORPHONE HCL
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-
Systematic Name English
OXYMORPHONE HYDROCHLORIDE [GREEN BOOK]
Common Name English
OXYMORPHONE HYDROCHLORIDE [WHO-DD]
Common Name English
OXYMORPHONE HYDROCHLORIDE [MI]
Common Name English
OXYMORPHONE HYDROCHLORIDE [USP]
Common Name English
4,5.ALPHA.-EPOXY-3,14-DIHYDROXY-17-METHYLMORPHINAN-6-ONE HYDROCHLORIDE
Systematic Name English
OXYMORPHONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
NUMORPHAN
Brand Name English
OPANA ER
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
NCI_THESAURUS C1506
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
Code System Code Type Description
EPA CompTox
357-07-3
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
FDA UNII
5Y2EI94NBC
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
CAS
357-07-3
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL963
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-610-5
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
DRUG BANK
DBSALT001249
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
MERCK INDEX
M8338
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY Merck Index
RXCUI
82064
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY RxNorm
PUBCHEM
5359390
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
EVMPD
SUB03591MIG
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
NCI_THESAURUS
C47648
Created by admin on Sat Jun 26 15:53:21 UTC 2021 , Edited by admin on Sat Jun 26 15:53:21 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Related Record Type Details
ACTIVE MOIETY